Moderna Inc. (NASDAQ:MRNA) will be the next company to bring a COVID-19 vaccine forward for authorization in adolescents, with plans to submit data from the Phase II/III TeenCOVE study of its COVID-19
Debiopharm will bank €188 million ($226.6 million) for pipeline development now that the biotech has partnered lead program xevinapant with Merck KGaA, adding the German biopharma’s